418 related articles for article (PubMed ID: 28931682)
1. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.
Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682
[TBL] [Abstract][Full Text] [Related]
2. Differential susceptibility of retroviruses to nucleoside analogues.
Rosenblum LL; Patton G; Grigg AR; Frater AJ; Cain D; Erlwein O; Hill CL; Clarke JR; McClure MO
Antivir Chem Chemother; 2001 Mar; 12(2):91-7. PubMed ID: 11527046
[TBL] [Abstract][Full Text] [Related]
3. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human endogenous retrovirus-K by antiretroviral drugs.
Tyagi R; Li W; Parades D; Bianchet MA; Nath A
Retrovirology; 2017 Mar; 14(1):21. PubMed ID: 28330477
[TBL] [Abstract][Full Text] [Related]
5. Genomic flexibility of human endogenous retrovirus type K.
Dube D; Contreras-Galindo R; He S; King SR; Gonzalez-Hernandez MJ; Gitlin SD; Kaplan MH; Markovitz DM
J Virol; 2014 Sep; 88(17):9673-82. PubMed ID: 24920813
[TBL] [Abstract][Full Text] [Related]
6. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
7. Human Endogenous Retrovirus Type K (HERV-K) Particles Package and Transmit HERV-K-Related Sequences.
Contreras-Galindo R; Kaplan MH; Dube D; Gonzalez-Hernandez MJ; Chan S; Meng F; Dai M; Omenn GS; Gitlin SD; Markovitz DM
J Virol; 2015 Jul; 89(14):7187-201. PubMed ID: 25926654
[TBL] [Abstract][Full Text] [Related]
8. New developments in anti-HIV chemotherapy.
De Clercq E
Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
10. New developments in anti-HIV chemotherapy.
De Clercq E
Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors.
Qari SH; Magre S; García-Lerma JG; Hussain AI; Takeuchi Y; Patience C; Weiss RA; Heneine W
J Virol; 2001 Jan; 75(2):1048-53. PubMed ID: 11134319
[TBL] [Abstract][Full Text] [Related]
12. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
Albright AV; Erickson-Viitanen S; O'Connor M; Frank I; Rayner MM; González-Scarano F
AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1527-37. PubMed ID: 11054266
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
Limoges J; Persidsky Y; Poluektova L; Rasmussen J; Ratanasuwan W; Zelivyanskaya M; McClernon DR; Lanier ER; Gendelman HE
Neurology; 2000 Jan; 54(2):379-89. PubMed ID: 10668699
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
Shi M; Wang X; De Clercq E; Takao S; Baba M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2600-4. PubMed ID: 17470654
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
